NovaRock Biotherapeutics

NovaRock Biotherapeutics, established in 2018, is an innovative and dynamic U.S.-based biotechnology company dedicated to developing novel antibody therapies for cancer and autoimmune diseases. NBL-015 is the second molecule developed by NovaRock Biotherapeutics to enter clinical trials. During the preclinical and discovery phases of development, NovaRock has several additional monoclonal and multispecific antibody molecules in its diversified pipeline.